Melanoma survival rates provide the proportion of people with a particular stage of melanoma who are alive after a predetermined amount of time, normally 5 or 10 years, after diagnosis.

In the CheckMate 238 trial, patients with resected stage IIIB–C or stage IV melanoma who were treated with nivolumab had longer recurrence-free survival than those who received ipilimumab. Data were needed on longer-term survival.

Australia has the highest incidence of skin cancer in the world. Current clinical guidelines do not recommend systematic skin cancer screening. However, in clinical practice many general practitioners do provide skin checks for their patients.

Visiting Sinclair Dermatology for a skin assessment is straightforward, comfortable, and designed with you in mind. Here's what happens from the moment you book your appointment.